Kentucky Pain Atlas · Medicaid Form Reform
Kentucky permits treatment above 200 MME. Its form still demands a plan to move below it.
That is not an absolute prescribing cap. It is a predetermined taper direction built into both Medicaid policy and the paperwork used to obtain payment.
Executive Finding
Kentucky’s problem is one sentence enforced in several places.
For opioid requests above 200 MME per day, Kentucky Medicaid requires clinical justification, specialist involvement, naloxone safeguards, and documentation of attempts or plans to taper below 200 MME.
Kentucky can preserve every legitimate safety review without predetermining the treatment destination.
Classification Method
Change the policy and the transaction together.
The written standard tells reviewers what evidence is required for authorization above 200 MME.
Items 26 and 43 carry the same taper direction into initial requests and renewals.
Portal questions and adjudication logic can preserve a deleted requirement unless changed at the same time.
Continuation, reduction, or tapering should follow documented benefit, risk, function, necessity, goals, alternatives, and specialist assessment.
The reform is complete only when fee for service Medicaid and the single managed care pharmacy benefit use the corrected standard.
Controlling Record
The form is part of the policy’s force.
The Kentucky Medicaid Pharmacy Prior Authorization Form directs all opioid requests through opioid specific pages. Its January 1, 2024 revision requires, at Item 26 for initial requests and Item 43 for renewals, documentation of attempts or plans to taper below 200 MME. Kentucky regulation 907 KAR 23:010 identifies the applicable Medicaid pharmacy prior authorization form within the authorization process.
Authorization above 200 MME remains possible with enhanced review and clinical justification.
The prescriber must also show that treatment is being moved, or is planned to move, below the state selected number.
Exact Request
Delete the predetermined taper direction.
Ask Kentucky DMS to make one coordinated correction across the opioid criteria, universal form, electronic questions, and adjudication workflow.
Remove the requirement that every request above 200 MME document attempts or plans to taper below 200 MME solely because the dosage crosses that threshold.
Require the prescriber to document whether continuation, dose reduction, or tapering is clinically appropriate for the individual patient.
Keep specialist involvement, clinical justification, KASPER review, benefit and risk assessment, naloxone precautions, nonopioid treatment components, and medical necessity review.
Change Item 26, Item 43, electronic prior authorization questions, MedImpact workflow, and every downstream copy of the condition at the same time.
Ready to Use Replacement Language
Keep heightened review. Remove the predetermined answer.
For requests above 200 MME per day: The prescriber shall document pain management specialist involvement, clinical justification for the requested dosage, current pain and functional status, material benefits and risks, relevant nonopioid treatment components, overdose precautions, and whether continuation at the current dosage, dose reduction, or tapering is clinically appropriate based on the member’s individualized circumstances.
If tapering is clinically appropriate: The treatment plan shall describe the proposed approach.
Universal form question: Has the prescriber documented whether continuation, reduction, or tapering is clinically appropriate based on an individualized benefit and risk assessment? Yes or No.
Conforming instruction: Remove any separate requirement that treatment above 200 MME must already be moving, or be planned to move, below 200 MME.
This is a public policy template, not medical or legal advice. Confirm the current criteria, form revision, question numbering, and submission channel immediately before use.
Action Sequence
Do not let a paper victory leave the form unchanged.
Archive the current opioid criteria, universal form, Pharmacy Policy Branch page, and portal instructions with retrieval dates.
Send DMS one request naming the criterion, Item 26, Item 43, electronic workflow, adjudication logic, and both Medicaid delivery systems.
Ask the Pharmacy and Therapeutics Committee to place the exact replacement language into its public clinical record.
Request records showing the origin, clinical basis, revision history, and contractor implementation of the taper condition.
After any approval, test the public form, portal questions, MedImpact workflow, fee for service process, and all five current managed care plans.
Measurable Results
Count operational removal.
A meeting or favorable statement is not completion. The condition must disappear from the governing criteria, the form a prescriber completes, and the system that decides the claim.
Internal Kentucky Evidence
Kentucky already uses the individualized alternative.
The form permits continuation at the current dose when the prescriber documents the rationale. That is individualized utilization review.
201 KAR 9:260 evaluates higher risk treatment in relation to benefit and permits documented clinical departure where a particular standard is inappropriate for the patient.
The 2022 CDC guideline supports flexible, person centered application and warns against inflexible payer rules that produce predetermined tapering.
Escalation and Off Ramp
Start where one decision can reach the whole system.
DMS policy, form, and workflow correction through the Pharmacy Policy Branch and public committee process.
Open records request if the agency cannot identify the origin, authority, evidence, or propagation of the requirement.
Legislative protection only if DMS declines individualized review or identifies a legal barrier it cannot remove.
Stop unnecessary escalation when DMS begins a complete correction. Help verify implementation and give public credit for meaningful progress.
Primary Source Record
Follow the requirement from rule to form to transaction.
Official records were checked for this revision. Policy documents, form numbers, portal workflows, and administrative regulations can change. Preserve dated copies and verify the current version before action.
Kentucky Closing Position
Enhanced review can remain. The predetermined destination should not.
Kentucky does not need to approve every request above 200 MME. It needs to decide each request without requiring the answer to be tapering before the patient’s evidence is reviewed.
Return to the request